Inovedis GmbH’s innovative implant - 28/03/2023 Next-generation minimally invasive shoulder surgery The treatment of shoulder injuries such as rotator cuff tears is one of the most common orthopaedic interventions. It is therefore quite surprising that the surgical procedure has not changed much for decades - although it is relatively complicated. The start-up Inovedis has now developed a completely new surgical technique based on an implant that can be performed simply, safely, quickly and cost-effectively with minimal stress for patients.
Development of anti-tumour agents - 20/03/2023 Targeting the protective shield of cancers Cancer cells have different mechanisms to help them escape destruction by the immune system. Solid tumours, for example, are often surrounded by a protective layer of lactate, which has a strong immunosuppressive effect. WMT AG from Heidelberg is developing small drug molecules that reduce lactate production and thus make cancer cells vulnerable to immune system attacks.
Expert interview - 08/03/2023 How do new active substances from university research reach patients? Access to capital remains one of the biggest challenges in the life sciences sector. Over the last two years, the Baden-Württemberg Center for Academic Drug Discovery (BWCAD2) has successfully implemented a model of cooperation between academic drug research and industry for the development and validation of therapeutic concepts. Dr. Barbara Jonischkeit spoke with the initiator and leading figure behind the BWCAD2 project, Prof. Dr. Stefan Laufer
Immune complexes in COVID-19 - 01/03/2023 Vicious circle of hyperinflammation Whether a person experiences only a mild malaise or a critical course of disease after a coronavirus infection apparently depends on the antigen-antibody complexes that form in our body. The discovery of these immune complexes set a group of researchers, headed up by Prof. Dr. Hartmut Hengel from the Freiburg University Medical Centre, on the trail of a vicious circle of constantly escalating inflammation.
Cytolytics GmbH - 14/02/2023 Bioinformatics meets medical diagnostics and drug development The start-up company Cytolytics from Tübingen has developed a robust and user-friendly software platform that uses machine learning for the automated analysis of cells. This is beneficial in areas such as cancer diagnostics and the development of new pharmaceutically active substances.
Review - 09/02/2023 5th Gene Technology Report – a critical observation of a cutting-edge technology The societal importance of genetic technologies was demonstrated during the coronavirus pandemic, when it was possible to rapidly develop suitable vaccines thanks to genetic engineering methods. As a result, the Fifth Gene Technology Report published in autumn 2021 reads like a validation of many years of work, as well as making it clear that the will to continue the detailed long-term monitoring is very much present.
Photon-counting technology - 01/02/2023 PC3 consortium: innovative computed tomography for Baden-Württemberg The University Hospitals of Freiburg, Tübingen and Mannheim have been cooperating with each other since 2021 to test new types of computed tomography devices. With the help of photon-counting technology, the aim is not only to improve patient care, but also to encourage local companies to develop downstream data processing technologies.
Automated pain recognition - 25/01/2023 Using artificial intelligence to improve pain management Psychologists from Ulm and their cooperation partners have developed algorithms for automated pain recognition in order to be able to dose painkillers more precisely. The researchers are now looking for industrial partners to take their project to application.
Value-based healthcare - 11/01/2023 High-quality healthcare pays off High-quality medical treatment is not only worthwhile for ill persons. The Division of Health Economics at the German Cancer Research Center in Heidelberg, headed up by Prof. Dr. Michael Schlander, together with researchers from Dresden, has carried out a cost-effectiveness analysis that shows that certified colon cancer centres provide not only better but also more cost-effective care than other clinics.
Neurodegenerative diseases - 12/12/2022 Blood-based biomarkers allow the early prediction of Alzheimer's risks Most dementia diseases develop insidiously and are only detected at an advanced stage. Researchers at the University of Heidelberg and the German Cancer Research Center (DKFZ) have now identified the glial fibre acidic protein (GFAP) in the blood as a promising biomarker that can be used to determine an increased risk of developing Alzheimer's disease up to 17 years before diagnosis.
Start-up Actimi GmbH - 23/11/2022 Real-time telemonitoring of heart failure Improved quality of life for patients and lower costs for health insurers: these are the advantages of telemonitoring patients with advanced heart failure. The Stuttgart-based start-up Actimi offers an all-in-one platform for those who treat and those who suffer from the disease.
Climate protection and sustainability in hospitals - 09/11/2022 Sustainable activities in the healthcare sector The healthcare sector is not only facing major challenges in dealing with the consequences of climate change on human health, but it also needs to make a concrete contribution to reducing its own greenhouse gas emissions. Analyses show there are many opportunities to make medical care more sustainable, especially in hospitals’ daily routines. This is where the Heidelberg University Hospital and the viamedica foundation from Freiburg come in.
